Maasilta P, Holsti L R, Blomqvist P, Kivisaari L, Mattson K
Department of Pulmonary Medicine, Helsinki University Central Hospital, Finland.
Radiother Oncol. 1992 Nov;25(3):192-5. doi: 10.1016/0167-8140(92)90267-x.
N-Acetylcysteine (NAC) is a free radical scavenger and could therefore act as a radioprotector. To test the feasibility of administering NAC in combination with radiotherapy, we studied 10 patients with inoperable non-small cell lung cancer who were receiving hyperfractionated radiotherapy (RT) of 1.25 Gy B.I.D. (6-h interval) up to a total dose of 60 Gy/48 fractions/32 days. They were given NAC concomitantly with RT: 100 mg/kg i.v. 30 min before the first RT session followed by 30 mg/kg as an i.v. infusion over 7 h; and 600 mg inhaled 30 min before and after each RT session. The patients were assessed by serial CT scans and lung function studies during a 1-year follow-up period. The treatment regime was feasible, but expensive in time and resources. Normal tissue reactions and tumour responses were similar to those in a control group.
N-乙酰半胱氨酸（NAC）是一种自由基清除剂，因此可作为一种辐射防护剂。为了测试联合使用NAC与放射治疗的可行性，我们研究了10例无法手术的非小细胞肺癌患者，这些患者正在接受每日两次、每次1.25 Gy（间隔6小时）的超分割放射治疗（RT），总剂量达60 Gy/48次/32天。他们在放疗期间同时给予NAC：首次放疗前30分钟静脉注射100 mg/kg，随后以30 mg/kg静脉输注7小时；每次放疗前后30分钟吸入600 mg。在1年的随访期内，通过系列CT扫描和肺功能研究对患者进行评估。该治疗方案可行，但在时间和资源方面成本高昂。正常组织反应和肿瘤反应与对照组相似。
